SelectQuote (SLQT) Q3 2026 earnings review
A Reaffirmed Outlook Masked by Accounting Noise
SelectQuote delivered ostensibly solid Q3 results with Revenue up 6% YoY to $430.9M and Adjusted EBITDA growing 18% to $44.6M, allowing management to comfortably reaffirm its FY26 guidance. However, a peek under the hood reveals questionable earnings quality. The Senior segment's touted 28% EBITDA growth was entirely fueled by a $14M positive change in estimate to commissions receivable. Stripping this out, Senior EBITDA actually declined YoY. Meanwhile, Healthcare Services margins remain severely compressed at 3%, failing to show the promised snapback after January 1st PBM rate adjustments. While the Revenue/CAC multiple hit a high of 6.7x, the underlying profit engine is relying heavily on balance sheet adjustments rather than cash-generating operational leverage.
🐂 Bull Case
The combined Senior and Healthcare Services Revenue to CAC multiple hit 6.7x (up from 5.8x a year ago). The company is extracting more value per marketing dollar than ever before.
SelectRx membership grew 11% YoY to over 116k, and prescriptions shipped per day reached 33k. The volume foundation remains intact despite industry headwinds.
🐻 Bear Case
Reported Net Income of $40.2M was massively padded by a $27.5M non-cash gain on warrant liabilities and the $14M commissions estimate change. Core operational profitability is much weaker than the headline suggests.
Despite previous management claims that PBM reimbursement rates would normalize on January 1, segment EBITDA fell 18% YoY to $5.3M on nearly $200M in revenue—a razor-thin 2.6% margin.
⚖️ Verdict: 🔴
Bearish. While reaffirming guidance provides relief after a chaotic H1, the heavy reliance on a $14M accounting adjustment to manufacture EBITDA growth in the core Senior segment is a major red flag.
Key Themes
Senior EBITDA Growth is an Accounting Illusion
The Senior segment reported a 28% YoY increase in Adjusted EBITDA to $58.6M. However, this includes a $14M positive change in estimate to commissions receivable. Without this adjustment, Senior segment EBITDA would have been approximately $44.6M, representing a slight YoY decline compared to last year's $45.7M. This completely contradicts the narrative of robust operational execution and highlights a heavy reliance on LTV tweaks to meet profitability targets.
Healthcare Services Profitability Remains Stalled
In H1 FY26, management blamed a $20M EBITDA headwind on a PBM reimbursement rate change, guiding that rates would return to 'normalized levels' on January 1, 2026. However, Q3 results show a segment struggling to convert volume to profit. Revenue grew 5% YoY to $199.4M, yet Adjusted EBITDA fell 18% to $5.3M. The margin sits at a sluggish 3%. The expected bounce-back has not materialized.
Unprecedented Marketing Efficiency
The company continues to extract more value from its customer acquisition funnel. The trailing 12-month Revenue to Customer Acquisition Cost (CAC) multiple accelerated to 6.7x, up from 5.8x in the prior year and 4.2x two years ago. Total operating expenses per MA/MS policy increased slightly, but the sheer growth in lifetime value capture—driven heavily by cross-selling the pharmacy base—proves the integrated ecosystem thesis is working at the top line.
SelectRx Volume Scale
While margins lag, the operational scale of SelectRx continues to grow. Total members reached 116,616 (up 11% YoY), and average prescriptions shipped per day accelerated to 33,209 (up 14% YoY). This scaled infrastructure provides immense leverage if the company can finally secure better pricing from its PBM partners.
Medicare Advantage Disruption
The broader Medicare Advantage market remains highly volatile. Regulatory changes, tighter CMS reimbursement rates, and carrier austerity measures have created significant friction for policy volumes. While SelectQuote frames this as an opportunity to capture churn, it introduces persistent uncertainty into their primary revenue engine.
AI and Automation Ecosystem
Management continues to successfully leverage technology to offset market pressures. The use of proprietary routing technology and AI for initial applicant scoring, real-time agent coaching, and plan ranking has demonstrably improved the efficiency of the enrollment process. This technological integration is the primary reason the company can sustain agent productivity despite market chaos.
Other KPIs
The sum of current ($76.8M) and long-term ($882.7M) commissions receivable continues to expand, up nearly $50 million over the past year. This nearly $1 billion asset represents future cash flows and acts as collateral for the company's securitization efforts, but the $14M positive adjustment in Q3 highlights the inherent subjectivity and risk tied to this balance.
Stable. The Life segment remains a reliable, if unexciting, cash generator. Revenue grew 4% to $47.9M, while EBITDA dipped slightly by 4% YoY. The 13% margin acts as a stabilizing anchor for the broader corporate structure.
Guidance
Reaffirmed. The midpoint of $1.66B implies an ~8.8% YoY acceleration compared to FY25's $1.526B. Maintaining this top-line target indicates confidence in SelectRx retention and Q4 volume expectations.
Reaffirmed. The midpoint of $95M implies a ~25% deceleration from FY25's $126.2M. This severe drop was priced in earlier this year due to PBM rate shocks and a major carrier pulling marketing spend, but avoiding a further downward revision is a minor victory for management.
Key Questions
Healthcare Services Margin Deficit
In H1, you guided that PBM reimbursement rates would return to normalized levels on January 1st. Yet, Q3 margins for Healthcare Services remain at just 3%. Why didn't profitability snap back as expected, and what is the new timeline for reaching acceptable margins?
Dependence on Accounting Adjustments
Without the $14M positive change in estimate to commissions receivable, Senior segment EBITDA would have declined year-over-year. How confident are you in core operational leverage given this reliance on LTV tweaks?
Warrant Liability Volatility
Net income was heavily distorted by a $27.5M change in warrant liability fair value. How should investors evaluate the underlying cash generation capacity when GAAP net income is so detached from operating reality?
SelectRx Capital Allocation
With Healthcare Services acting as a drag on consolidated margins, at what point does management reconsider the capital allocated to scaling SelectRx versus returning cash to shareholders or accelerating debt paydown?